AnaptysBio (ANAB) Fundamental Analysis: Revenue, Earnings & Valuation

2.54 / 10

Underperform

Fundamental rating is Underperform (2.5/10). Profit‑MV and Cash‑MV are strong, and inventory turnover is efficient, but Revenue‑MV and Asset‑MV are negative, dragging the score. Gross margin is high (100%) yet overall financial health remains challenged.

Analysis Checks(7/10)

Revenue-MV

Value-0.61

Score1/3

Weight12.94%

1M Return5.44%

Inventory turnover ratio

Value106.57

Score3/3

Weight15.71%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.33%

1M Return1.67%

Profit-MV

Value0.68

Score2/3

Weight14.78%

1M Return6.36%

Income tax / Total profit (%)

Value-1.25

Score2/3

Weight1.86%

1M Return0.98%

Current assets turnover ratio

Value0.60

Score1/3

Weight-0.32%

1M Return-0.17%

Fixed assets turnover ratio

Value145.76

Score2/3

Weight0.02%

1M Return0.01%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight7.81%

1M Return4.08%

Asset-MV

Value-0.55

Score1/3

Weight29.40%

1M Return11.48%

Cash-MV

Value0.74

Score2/3

Weight14.48%

1M Return6.19%

Is ANAB undervalued or overvalued?

ANAB scores 2.54/10 on fundamentals and holds a Premium valuation at present. Backed by its -24.49% ROE, -5.64% net margin, -124.71 P/E ratio, 44.35 P/B ratio, and 91.02% earnings growth, these metrics solidify its Underperform investment rating.